Data_Sheet_1_Immunometabolic Network Interactions of the Kynurenine Pathway in Cutaneous Malignant Melanoma.zip (620.77 kB)

Data_Sheet_1_Immunometabolic Network Interactions of the Kynurenine Pathway in Cutaneous Malignant Melanoma.zip

Download (620.77 kB)
dataset
posted on 03.02.2020, 14:49 by Soudabeh Rad Pour, Hiromasa Morikawa, Narsis A. Kiani, David Gomez-Cabrero, Alistair Hayes, Xiaozhong Zheng, Maria Pernemalm, Janne Lehtiö, Damian J. Mole, Johan Hansson, Hanna Eriksson, Jesper Tegnér

Dysregulation of the kynurenine pathway has been regarded as a mechanism of tumor immune escape by the enzymatic activity of indoleamine 2, 3 dioxygenase and kynurenine production. However, the immune-modulatory properties of other kynurenine metabolites such as kynurenic acid, 3-hydroxykynurenine, and anthranilic acid are poorly understood. In this study, plasma from patients diagnosed with metastatic cutaneous malignant melanoma (CMM) was obtained before (PRE) and during treatment (TRM) with inhibitors of mitogen-activated protein kinase pathway (MAPKIs). Immuno-oncology related protein profile and kynurenine metabolites were analyzed by proximity extension assay (PEA) and LC/MS-MS, respectively. Correlation network analyses of the data derived from PEA and LC/MS-MS identified a set of proteins that modulate the differentiation of Th1 cells, which is linked to 3-hydroxykynurenine levels. Moreover, MAPKIs treatments are associated with alteration of 3-hydroxykynurenine and 3hydroxyanthranilic acid (3HAA) concentrations and led to higher “CXCL11,” and “KLRD1” expression that are involved in T and NK cells activation. These findings imply that the kynurenine pathway is pathologically relevant in patients with CMM.

History

References

Licence

Exports